x
CME-Tagline

Creating Action Steps for Linking Underserved Populations with Hepatitis C Care

CMEO Webcast

Premiere Date: Tuesday, April 20, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Tuesday, December 20, 2022

Faculty


Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD (Moderator)
President, Inova Medicine Services
Chairman, Clinical Research, Inova Health System
Professor and Chairman of Department of Medicine
Inova Fairfax Medical Campus
Falls Church, VA

Barbra Cave, PhD, APRN, FNP-BC Barbra Cave, PhD, APRN, FNP-BC 
Assistant Professor
University of Louisville School of Medicine
Christina Lee Brown Envirome Institute
Division of Environmental Health
Hep C Program Lead
University of Louisville Hospital Hep C Center
Louisville, KY

Anthony Martinez, MD, AAHIVS, FAASLD Anthony Martinez, MD, AAHIVS, FAASLD 
Associate Professor of Medicine
Jacobs School of Medicine
University at Buffalo
Medical Director, Hepatology
Erie County Medical Center
Buffalo, NY

Christian B. Ramers, MD, MPH, AAHIVS Christian B. Ramers, MD, MPH, AAHIVS 
Chief, Population Health Department
Medical Director, Laura Rodriguez Research Institute
ACGME Designated Institutional Official
Family Health Centers of San Diego
Clinical Associate Professor - UC San Diego School of Medicine
Adjunct Associate Professor - SDSU School of Public Health
Senior Clinical Advisor - Clinton Health Access Initiative, Global Hepatitis Program
San Diego, CA

Statement of Need

Hepatitis C virus (HCV) is known as a "silent epidemic" because a large proportion of individuals living with HCV are asymptomatic or have mild symptoms and do not seek medical care. The Centers for Disease Control and Prevention (CDC) estimates that for every reported HCV infection there are 13.9 undiagnosed cases. The rise in HCV infections, particularly among younger demographics, is driven by injection drug use (IDU). Challenges in controlling the impact of HCV include low screening, treatment initiation rates, and patient education, particularly among high-risk and medically underserved populations.

In this CME Outfitters Live and OnDemand webcast, expert faculty will discuss the many barriers to treating HCV in the IDU population, including stigma and established negative perceptions about people who inject drugs (PWID), with special attention paid to applying CDC universal screening guidelines to improve diagnosis and linkage to treatment, expanding treatment for HCV in primary care settings, and addressing disparities in HCV treatment initiation in underserved communities.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply CDC universal screening guidelines to improve diagnosis of HCV and linkage to treatment.
  • Expand treatment for HCV in primary care settings using simplified algorithms for screening, treatment, and patient monitoring.
  • Address disparities in HCV treatment initiation in underserved rural and Federally Qualified Health Centers (FQHCs).

The following learning objectives pertain only to those requesting CNE credit:

  • Summarize the CDC universal screening guidelines to improve diagnosis of HCV and linkage to treatment.
  • Explain how to expand treatment for HCV in primary care settings using simplified algorithms for screening, treatment, and patient monitoring.
  • Address disparities in HCV treatment initiation in underserved rural and FQHCs.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, emergency medicine clinicians, addiction specialists, nurse practitioners, PAs, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Enduring: 0376-0000-21-042-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Younossi reports that he receives research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; and Siemens. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; and Terns Pharmaceuticals, Inc.

Dr. Cave reports that she receives grants from Gilead Sciences, Inc. She is on the speakers bureau and advisory board for AbbVie Inc. and Gilead Sciences, Inc.

Dr. Martinez reports that he receives research support from AbbVie Inc.; Allergan; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc. He is on the speakers bureau for AbbVie Inc.; Eisai Inc.; and Gilead Sciences, Inc. He is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.

Dr. Ramers reports that he receives grants from AbbVie Inc. and Gilead Sciences, Inc. He receives research support from Gilead Sciences, Inc. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; and Viiv Healthcare. He is a consultant for AbbVie Inc.; Gilead Sciences, Inc.; and Theratechnologies Inc.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Michael J. Franks, MSN, AGACNP-BC, FNP, BC (peer reviewer) has no disclosures to report.

Noreen Iftikhar, MD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TV-127-042021-47